Avid A17 Study Continuation
Avid Radiopharmaceuticals Study 45-A17
With thanks to The Clinical Research Division of Hampton Health, Ltd.™ for participating in the 2011-2012 AVID 18F-AV-45-A17 Study, Avid Radiopharmaceuticals announced plans for an extension of the AVID 45-A17 Study in February 2013 with the continued participation of Dr. John H. Fullerton and the Hampton Health, Ltd.™ Clinical Research Division.
AVID noted "their gratification from our group efforts which has also resulted in a recent publication in the Alzheimer’s Disease and Associated Disorders Journal."
The goal of the A24 study, which The Hampton Health, Ltd.™ Clinical Research Division completed in July 2013, tracked the actual management of patients who participated in the original A17 Study which had focused on respondents age 50 and above who experienced some form of memory loss, (including MCI – Mild Cognitive Impairment), and became part of a compensated study which utilized a specifically designed PET scan with the unique radiopharmaceutical compound Amyvid™ or florbetapir F 18 for the augmented detection of Alzheimer’s Disease.
Dr. John H. Fullerton, Founder and CMO of Hampton Health, Ltd.™ returned to lead the continuation A24 Study as Principal Investigator.